Revealing brain temperature via MR imaging and biophysical modeling

A combination of MRI and biophysical modeling could provide more accurate predictions of brain Read more

Trailblazer award for MR monitoring brain temperature

NIBIB R21 "Trailblazer" award to monitor brain temperature while patients undergo therapeutic hypothermia after cardiac Read more

COVID-19 vaccine-generated antibodies last at least 6 months

How long does COVID-19 vaccine-generated immunity last? New laboratory results provide a partial answer to that Read more

Alzheimer’s Association

Welcome to the heat: Alzheimer’s Breakthrough Ride

Thomas Kukar, a new Emory faculty member in pharmacology, is participating in a charity bicycle ride for Alzheimer’s disease research called the Alzheimer’s Breakthrough Ride. On Thursday and Friday, he will be riding from Oklahoma City, OK to Wichita, KS. Tomorrow’s ride is 100 miles, and it’s supposed to be 97°F in Wichita.

Thomas Kukar, PhD

Kukar’s willingness to take on this challenge indicates that he shouldn’t have too much trouble adjusting to Atlanta’s climate. He comes to Emory from the Mayo Clinic in Jacksonville. There, he investigated potential drugs that could change how the body produces and processes beta-amyloid, a toxic protein fragment that builds up in the brains of people with Alzheimer’s.

The money raised by the bicycle ride goes to the Alzheimer’s Association.

Posted on by Quinn Eastman in Uncategorized Leave a comment

Alzheimer’s expert weighs in on proposed guidelines

Scans can show beta amyloid, a protein associated with Alzheimer’s disease (right)

For the first time in 25 years, medical experts are proposing new diagnostic criteria aimed at better and earlier detection of Alzheimer’s disease (AD).

The guidelines, proposed by the National Institute on Aging (NIA) and the Alzheimer’s Association, update and revise the current Alzheimer’s criteria with modern technologies and the latest research advances.

According to the Alzheimer’s Association, an estimated 5.3 million Americans have AD, most of them 65 and older. The disease is thought to begin years, possibly even decades, before symptoms are noticeable. But there is no single, generally accepted way to identify the disease in its earliest stages before symptoms are evident.

The new diagnostic guidelines focus on advances in detecting biomarkers for the disease, such as substances found in spinal fluid or appearing on cutting-edge brain imaging scans conducted with PET or MRI.

Emphasis will be on diagnosing early stages of the disease as soon as possible so that patients can take measures to slow the progression or prevent further damage.

Read more

Posted on by admin in Neuro Leave a comment